Biomarkers of outcome in rheumatoid arthritis
Rheumatology Reports · 2010
DOI: 10.4081/rr.2010.e3 ↗At a glance
Journal article in Rheumatology Reports, 2010. Written by Roberto Carrasco and 1 co-authors. Cited 8 times so far (Crossref).
Abstract (original language)
Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis, affecting approximately 1% of the population. This systemic disease is marked by chronic inflammation that predominantly affects the synovial membrane of diarthrodal joints. Its etiology is unknown, but it is presumed to be an immunological disease with contributing genetic and environmental factors. Evidence suggests that RA develops in 3 phases: an asymptomatic period of genetic risk, a pre-clinical period in which RA-related antibodies can be detected, and a clinical phase with acute signs and symptoms of inflammatory arthritis. Evidence suggests that the sooner RA patients are treated, the better is their prognosis. The availability of markers that could help to identify patients with more aggressive, rapidly progressive RA with poorer prognosis would offer a rational basis for early and aggressive treatment. In that way it may be possible to avoid many irreversible clinical complications. The number of disease modifying anti-rheumatic drugs (DMARD) available has increased in recent years. The effectiveness, cost and toxicity of the new agents vary widely and the natural history of RA itself includes spontaneous remission, remission with medical treatment or continuously progressive disease despite medication. Hence, there is a clear need to identify efficient diagnostic and prognostic indicators of disease to assist clinicians and help them in making initial treatment choices. This article is a literature review of current biomarkers to aid in the diagnosis of RA and emerging predictive markers of prognosis, but is non-systematic and therefore may be subject to publication and selection biases. No attempt has been made to assess the validity of studies or to compare risks between studies. Our aim was to review the literature in an inclusive manner.
Cite
APA
Carrasco, R., & Barton, A. (2010). Biomarkers of outcome in rheumatoid arthritis. Rheumatology Reports. https://doi.org/10.4081/rr.2010.e3
Vancouver
Carrasco R, Barton A. Biomarkers of outcome in rheumatoid arthritis. Rheumatology Reports. 2010. doi:10.4081/rr.2010.e3
BibTeX
@article{Carrasco2010,
author = {Carrasco, Roberto and Barton, Anne},
title = {Biomarkers of outcome in rheumatoid arthritis},
journal = {Rheumatology Reports},
year = {2010},
doi = {10.4081/rr.2010.e3}
}
EUVIMED